Corner J A, Rawoot A, Parmar H V
Department of Orthopaedic Surgery, Queen Elizabeth II Hospital, Welwyn Garden City, Hertfordshire, UK.
Hip Int. 2008 Apr-Jun;18(2):88-94. doi: 10.1177/112070000801800204.
The thrust plate prosthesis (TPP) is a neck preserving femoral component in total hip arthroplasty (THA). We present our mid-term results from using the thrust plate prosthesis in young patients with hip arthritis. We conducted a retrospective review of a consecutive series of patients with a minimum of 5 years follow-up after total hip arthroplasty using the thrust plate prosthesis. Harris Hip Score (HHS) and Oxford Hip Score (OHS) were recorded preoperatively and at the last clinical review. Radiographic analysis was performed and patient satisfaction levels and complications were recorded. Between 1996 and 2000 we implanted 41 prostheses in 38 consecutive patients (3 bilateral). The mean age at time of surgery was 56 years (41-67) and the mean length of follow-up was 71 months. The HHS improved from a mean of 42 points preoperatively to 88 points at the last clinical review and the mean OHS also improved from 40 points to 18 points. Eighty-three percent of patients expressed that they were 'very satisfied' with the procedure. Implant survivorship was 95% at 5 years follow-up with revision surgery being the end point. Eight patients suffer discomfort when lying on the operated side. Many patients treated with the TPP show excellent improvement in clinical outcome scores and a high level of patient satisfaction but the complication rate gives some concern. We support the selective use of the TPP to treat young patients with hip osteoarthritis.
推力板假体(TPP)是全髋关节置换术(THA)中一种保留股骨颈的假体组件。我们展示了在年轻髋关节炎患者中使用推力板假体的中期结果。我们对一系列连续的患者进行了回顾性研究,这些患者在使用推力板假体进行全髋关节置换术后至少随访了5年。术前和最后一次临床复查时记录了Harris髋关节评分(HHS)和牛津髋关节评分(OHS)。进行了影像学分析,并记录了患者满意度水平和并发症情况。1996年至2000年间,我们为38例连续患者(3例双侧)植入了41个假体。手术时的平均年龄为56岁(41 - 67岁),平均随访时间为71个月。HHS从术前的平均42分提高到最后一次临床复查时的88分,平均OHS也从40分提高到18分。83%的患者表示对该手术“非常满意”。以翻修手术为终点,5年随访时假体生存率为95%。8例患者在患侧卧位时感到不适。许多接受TPP治疗的患者临床结局评分有显著改善,患者满意度较高,但并发症发生率令人担忧。我们支持选择性使用TPP治疗年轻髋骨关节炎患者。